Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.39
+1.6%		$5.24
$2.87
▼
$6.45
$346.48M0.39289,232 shs390,039 shs
CCXI
Churchill Capital Corp XI
$10.48
-1.7%		$13.06
$10.07
▼
$19.69
$747.81M1.221.69 million shs1.51 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$14.18
+0.9%		$13.40
$9.77
▼
$16.33
$2.45B0.1858,945 shs28,370 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
+1.62%-12.72%-17.64%-9.86%+43.46%
CCXI
Churchill Capital Corp XI
-1.69%-2.78%-18.76%-29.33%+1,047,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+0.93%+3.65%+3.73%+26.83%-6.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.39
+1.6%		$5.24
$2.87
▼
$6.45
$346.48M0.39289,232 shs390,039 shs
CCXI
Churchill Capital Corp XI
$10.48
-1.7%		$13.06
$10.07
▼
$19.69
$747.81M1.221.69 million shs1.51 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$14.18
+0.9%		$13.40
$9.77
▼
$16.33
$2.45B0.1858,945 shs28,370 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
+1.62%-12.72%-17.64%-9.86%+43.46%
CCXI
Churchill Capital Corp XI
-1.69%-2.78%-18.76%-29.33%+1,047,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+0.93%+3.65%+3.73%+26.83%-6.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$7.0059.45% Upside
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.67
Moderate Buy$14.874.84% Upside

Current Analyst Ratings Breakdown

Latest CCXI, AVIR, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/8/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy
9/3/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy
8/18/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (D)
8/13/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$6.00 ➝ $7.00
8/3/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E)
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$16.00 ➝ $14.00
(Data available from 10/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$3.53 per shareN/A
CCXI
Churchill Capital Corp XI
$37.20M20.10N/AN/AN/A∞
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.51$2.72 per share5.21$7.17 per share1.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.08N/AN/AN/AN/A-64.25%-57.12%11/11/2026 (Estimated)
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A64.45N/AN/AN/AN/AN/A

Latest CCXI, AVIR, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.51N/AN/AN/A$50.45 millionN/A
8/12/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550-$0.41+$0.1450-$0.41$33.03 millionN/A
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.13
8.13
CCXI
Churchill Capital Corp XI
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
CCXI
Churchill Capital Corp XI
81.09%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
CCXI
Churchill Capital Corp XI
8.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
5580.21 million62.88 millionOptionable
CCXI
Churchill Capital Corp XI
271.36 millionN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable

Recent News About These Companies

HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings
October 18 at 1:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/hutchmed-aim-hcm-stock-looks-041753501.html
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts
October 16, 2026  |  defenseworld.netD
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Rated "Moderate Buy" by Sell-Side Brokerages
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-hutchmed-china-limited-sponsored-adr-nasdaq-hcm-stock-rated-moderate-buy-by-sell-side-brokerages-2026-10-13/
How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo
October 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/investors-may-respond-hutchmed-china-031648737.html
Citic Securities Remains a Buy on HUTCHMED (China) (HCM)
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HCM/pressreleases/4525963/citic-securities-remains-a-buy-on-hutchmed-china-hcm/
ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill
October 3, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/03/adp-warns-of-cooling-labor-market-while-its-own-business-feels-the-chill/?utm_source=snapi
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
September 28, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-files-us-fda-application-hutchmed-lung-cancer-drug-combination-2026-09-29/
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370345/0/en/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer.html
HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694124/hutchmed-starts-global-phase-1-trial-of-kras-egfr-therapy-hmpl-a830-in-solid-tumors.aspx
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369472/0/en/hutchmed-initiates-global-trial-of-kras-egfr-antibody-conjugate-therapy-hmpl-a830-in-patients-with-solid-tumors.html
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3367914/0/en/hutchmed-highlights-clinical-data-to-be-presented-at-the-esmo-congress-2026.html
HUTCHMED stock holds at USD 13.67 as market cap reaches USD 2.376 billion
September 22, 2026  |  ad-hoc-news.deA
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow
September 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943635-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942785-hutchmed-china-limited-hcm-discusses-strategic-partnership-with-gsk-and-licensing-of-oncology
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688056/hutchmed-licenses-hmpl-a830-to-gsk-in-1-295-bln-deal-for-cancer-therapy-stock-up-14.aspx
Hutchmed strikes licensing agreement with GSK
September 3, 2026  |  thepharmaletter.comT
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098046?snapi
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
September 3, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1098034?snapi
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
September 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/hutchmed-china-signs-licensing-deal-with-gsk-experimental-solid-tumour-drug-2026-09-03/
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355629/0/en/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-therapy.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$4.39 +0.07 (+1.62%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$4.39 +0.00 (+0.11%)
As of 10/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Churchill Capital Corp XI NASDAQ:CCXI

$10.48 -0.18 (-1.69%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$10.50 +0.03 (+0.24%)
As of 06:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$14.18 +0.13 (+0.93%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$14.66 +0.48 (+3.42%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas